Loris Piccolo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Loris Piccolo has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Cosimo Zaccaria
European Medicines Agency, Amsterdam, Netherlands
2 shared publications - Corinne de Vries
European Medicines Agency, Amsterdam, The Netherlands
1 shared publication - Elena Rocca
Faculty of Health Sciences, Institute for Natural Science and Health Oslo Metropolitan University Oslo Norway
1 shared publication - Gilles Touraille
European Medicines Agency, Amsterdam, The Netherlands
1 shared publication - Levente Kiss-Papai
Uppsala Monitoring Centre, Uppsala, Sweden
1 shared publication - Lovisa Sandberg
Uppsala Monitoring Centre, Uppsala, Sweden
1 shared publication
Latest Publications
- Open Access
Comparing Existing Algorithms for Retrieving Pregnancy-related Adverse Event Reports
Background: Post-marketing surveillance is essential for complementing the safety profiles of medicinal products, especially for populations generally excluded from clinical trials such as pregnant individuals. However, the absence of a standardised pregnancy indicator in the electronic transmissions of adverse event reports hampers their correct identification in pharmacovigilance databases and complicates the study of safety concerns related to pregnancy exposures. Three recently developed rule-based algorithms with the common aim to systematically retrieve pregnancy-related reports differ in scope and are tailored to different databases (A. FAERS, B. EudraVigilance, C. VigiBase). Aim: To compare the design and outputs of the three pregnancy algorithms. Methods: This study was a collaboration among the authors of the three pregnancy algorithms. We harmonised their rules, implemented them in an R package to enable execution in both VigiBase and FAERS, and analysed key characteristics of reports flagged by each algorithm. Results: The pregnancy algorithms A, B, and C flagged 235653, 279515, and 446957 reports respectively in VigiBase, and 265015, 260734, 350479 in FAERS. Reports exclusively retrieved by each algorithm (994, 3248, and 142324 in VigiBase, and 1528, 1100, and 59643 in FAERS) were mostly explained by Algorithm A having no age restriction, Algorithm B excluding normal pregnancy and ineffective contraception, and Algorithm C excluding paternal exposure. Conclusions: Differences in flagging were largely related to varying scopes. Understanding commonalities and differences is crucial for empowering professionals working with pregnancy-related pharmacovigilance to select and use the most appropriate algorithm for their specific needs. Key points: Three independently developed algorithms were designed to retrieve pregnancy-related adverse event reports and support research into pregnancy-specific safety concerns. By applying these algorithms to VigiBase and FAERS, we highlighted overlaps and differences in the reports they flag, reflecting heterogeneous scope and implementation. Awareness of these distinctions is essential to select and apply the most suitable algorithm for their specific needs.
Open AccessComparing Existing Algorithms for Retrieving Pregnancy-related Adverse Event Reports
Background: Post-marketing surveillance is essential for complementing the safety profiles of medicinal products, especially for populations generally excluded from clinical trials such as pregnant individuals. However, the absence of a standardised pregnancy indicator in the electronic transmissions of adverse event reports hampers their correct identification in pharmacovigilance databases and complicates the study of safety concerns related to pregnancy exposures. Three recently developed rule-based algorithms with the common aim to systematically retrieve pregnancy-related reports differ in scope and are tailored to different databases (A. FAERS, B. EudraVigilance, C. VigiBase). Aim: To compare the design and outputs of the three pregnancy algorithms. Methods: This study was a collaboration among the authors of the three pregnancy algorithms. We harmonised their rules, implemented them in an R package to enable execution in both VigiBase and FAERS, and analysed key characteristics of reports flagged by each algorithm. Results: The pregnancy algorithms A, B, and C flagged 235653, 279515, and 446957 reports respectively in VigiBase, and 265015, 260734, 350479 in FAERS. Reports exclusively retrieved by each algorithm (994, 3248, and 142324 in VigiBase, and 1528, 1100, and 59643 in FAERS) were mostly explained by Algorithm A having no age restriction, Algorithm B excluding normal pregnancy and ineffective contraception, and Algorithm C excluding paternal exposure. Conclusions: Differences in flagging were largely related to varying scopes. Understanding commonalities and differences is crucial for empowering professionals working with pregnancy-related pharmacovigilance to select and use the most appropriate algorithm for their specific needs. Key points: Three independently developed algorithms were designed to retrieve pregnancy-related adverse event reports and support research into pregnancy-specific safety concerns. By applying these algorithms to VigiBase and FAERS, we highlighted overlaps and differences in the reports they flag, reflecting heterogeneous scope and implementation. Awareness of these distinctions is essential to select and apply the most suitable algorithm for their specific needs.
- Open Access
- 19 June 2024
- Published by Springer Nature in Drug Safety
- Vol. 47 (11) , 1127-1136
Identification of Pregnancy Adverse Drug Reactions in Pharmacovigilance Reporting Systems: A Novel Algorithm Developed in EudraVigilance
Introduction There is a need to strengthen the evidence base regarding medication use during pregnancy and to facilitate the early detection of safety signals. EudraVigilance (EV) serves as the primary system for managing and analysing information concerning suspected adverse drug reactions (ADRs) within the European Economic Area. Despite its various functionalities, the current format for electronic submissions of safety reports lacks a specific data element indicating medicine exposure during pregnancy. Objective This paper aims to address the limitations of existing approaches by developing a rule-based algorithm in EV that more reliably identifies cases that are truly representative of an ADR during pregnancy. Methods The study utilised the standardised MedDRA query (SMQ) 'Pregnancy and neonatal topics' (PNT) as a benchmark for comparison. Recognising that the SMQ PNT also retrieves healthy pregnancy outcomes, contraceptive failure, failed abortifacients as well as ADRs not associated with pregnancy, a novel algorithm was tailored to improve the accuracy of identifying suspected ADRs occurring during pregnancy. Results Upon testing, the algorithm demonstrated superior performance, correctly predicting 90% of cases reporting an ADR during pregnancy, compared to 54% achieved by the SMQ PNT. The implementation of the algorithm in EV led to the retrieval of 202,426 cases. Conclusion The development and successful testing of the novel algorithm represents a step forward in pregnancy-specific signal detection in EV. Because signals associated with pregnancy may be diluted in a large database such as EV, this study lays the groundwork for future research to evaluate the effectiveness of disproportionality methods on a more refined subset of pregnancy-related ADR reports.
- 19 June 2024
- Published by Springer Nature in Drug Safety
- Vol. 47 (11) , 1127-1136
Open AccessIdentification of Pregnancy Adverse Drug Reactions in Pharmacovigilance Reporting Systems: A Novel Algorithm Developed in EudraVigilance
Introduction There is a need to strengthen the evidence base regarding medication use during pregnancy and to facilitate the early detection of safety signals. EudraVigilance (EV) serves as the primary system for managing and analysing information concerning suspected adverse drug reactions (ADRs) within the European Economic Area. Despite its various functionalities, the current format for electronic submissions of safety reports lacks a specific data element indicating medicine exposure during pregnancy. Objective This paper aims to address the limitations of existing approaches by developing a rule-based algorithm in EV that more reliably identifies cases that are truly representative of an ADR during pregnancy. Methods The study utilised the standardised MedDRA query (SMQ) 'Pregnancy and neonatal topics' (PNT) as a benchmark for comparison. Recognising that the SMQ PNT also retrieves healthy pregnancy outcomes, contraceptive failure, failed abortifacients as well as ADRs not associated with pregnancy, a novel algorithm was tailored to improve the accuracy of identifying suspected ADRs occurring during pregnancy. Results Upon testing, the algorithm demonstrated superior performance, correctly predicting 90% of cases reporting an ADR during pregnancy, compared to 54% achieved by the SMQ PNT. The implementation of the algorithm in EV led to the retrieval of 202,426 cases. Conclusion The development and successful testing of the novel algorithm represents a step forward in pregnancy-specific signal detection in EV. Because signals associated with pregnancy may be diluted in a large database such as EV, this study lays the groundwork for future research to evaluate the effectiveness of disproportionality methods on a more refined subset of pregnancy-related ADR reports.